Zin Htut

Zin Htut

Auto-generated profile, based on publicly available information

Zin Htut

Imperial College London, London, United Kingdom

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2026 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
ZHZin Htut
Zin Htut
AMAastha Mundhra
Aastha Mundhra
KLKatharine Lazarus
Katharine Lazarus
NMNiamh Martin
Niamh Martin
DPDebbie Papadopoulou
Debbie Papadopoulou
FWFlorian Wernig
Florian Wernig
Context: Adrenocorticotropic hormone (ACTH)–dependent Cushing syndrome (CS) is associated with a markedly increased risk of venous thromboembolism (VTE), yet thromboprophylaxis strategies remain inconsistent across clinical practice. In 2019, our center introduced routine oral rivaroxaban prophylaxis (10 mg once daily) for all patients with ACTH-dependent CS. Objective: To evaluate the safety and effectiveness of routine rivaroxaban prophylaxis in ACTH-dependent CS. Methods: We retrospectively reviewed 70 adults with ACTH-dependent CS managed between 2012 and 2025 (29 pre-2019 and 41 post-2019) to compare VTE incidence before and after the introduction of rivaroxaban. Results: There were no differences in baseline characteristics between the 2 groups. Cushing disease (ie, secondary to a pituitary corticotroph adenoma) was the most common subtype (26/29 pre-2019 and 34/41 post-2019). Among patients without routine prophylaxis (pre-2019), 4 patients (13.8%) developed 6 VTE events, occurring both pre- and postoperatively. In the post-2019 cohort, 5 patients experienced 7 VTE events before endocrine assessment and before rivaroxaban could be initiated. Two had recurrent VTE and were already receiving long-term treatment-dose anticoagulation; therefore, 39 of the 41 proceeded with rivaroxaban prophylaxis. No major or minor bleeding complications were observed. Hematological parameters remained stable, and all patients completed the prescribed prophylaxis course (median duration: 7.9 months). Conclusion: In our cohort, VTE incidence was 13.8% without prophylaxis and did not occur after the introduction of routine rivaroxaban. Prophylactic oral rivaroxaban in ACTH-dependent CS was safe and effective in preventing new, recurrent, perioperative, and postoperative VTE events, supporting its early initiation at diagnosis and continuation through the peri- and postoperative period.

1 February 2026 in Endocrine Connections
Verified
Journal Article
Open access
ESEmmanuel Ssemmondo
Emmanuel Ssemmondo
KLKatharine Lazarus
Katharine Lazarus
MNMilly Newham
Milly Newham
KNKavita Narula
Kavita Narula
ZHZin Htut
Zin Htut
KMKarim Meeran
Karim Meeran
Background: Patients with adrenal insufficiency require glucocorticoid replacement therapy either as hydrocortisone in multiple-daily doses or as low-dose prednisolone once daily. Data on the long-term safety, cardiovascular risk, and quality-of-life (QoL) outcomes of prednisolone remain limited. Methods: In this prospective longitudinal cohort study, patients with adrenal insufficiency underwent a pre-specified switch from multiple-daily dose hydrocortisone to once-daily low-dose prednisolone (2–4 mg) as part of routine clinical care and followed up for at least four months. Cardiovascular risk was assessed using anthropometric and biochemical markers (lipid profile, HbA1c, C-reactive protein, blood pressure, and waist and hip circumference). QoL was evaluated using a modified SF-36 questionnaire. Baseline and follow-up measures were compared using paired t-tests or non-parametric equivalents. Results: Of the 62 enrolled patients, 48 completed follow-up. The mean age was 54.5 ± 13 years; 56% were female; and 83% had secondary adrenal insufficiency. After at least four months on prednisolone, weight decreased significantly (90.6–89.6 kg, P = 0.007), accompanied by a reduction in systolic blood pressure (−5 mmHg, P = 0.032). Lipid parameters, HbA1c, and CRP remained unchanged (P > 0.05). Energy scores improved significantly (+9 points, P = 0.003), and patients reported increased treatment convenience (P = 0.002). Conclusion: Low-dose once-daily prednisolone offers comparable cardiovascular risk to hydrocortisone while improving treatment convenience, systolic blood pressure, and SF-36 subjective energy scores. These findings support the use of prednisolone as a potentially preferable alternative in patients with adrenal insufficiency.

1 January 2026 in Endocrine Connections
Verified
Journal Article
Open access
RMRajeev Mehta
Rajeev Mehta
KLKatharine Lazarus
Katharine Lazarus
ASAngelica Sharma
Angelica Sharma
PEPei Chia Eng
Pei Chia Eng
KNKavita Narula
Kavita Narula
KMKarim Meeran
Karim Meeran
Objective: Glucocorticoid discontinuation is complicated by glucocorticoid-induced adrenal insufficiency. Guidelines discourage tapering below physiological doses (prednisolone 3–6 mg) when morning cortisol is ≤300 nmol/L, with values <150 nmol/L thought to indicate persistent adrenal insufficiency, although this may underestimate hypothalamic–pituitary–adrenal axis suppression from such doses. We aim to evaluate how hypothalamic–pituitary–adrenal axis function evolves during physiological dose tapering and assess whether current cortisol thresholds restrict successful discontinuation. Design: This is a retrospective cohort study. Methods: Adults (n = 65) with long-term glucocorticoid use for inflammatory disease undergoing prednisolone tapering between 2019 and 2024 were included. Serial short Synacthen tests (n = 52) on reducing prednisolone doses (≤5 mg) were analysed using linear mixed-effects modelling. Nadir morning cortisol values at doses ≤5 mg from successful weans were compared with guideline thresholds. Results: At referral, the mean age was 55.4 ± 16.4 years, with median prednisolone dose and duration of therapy being 5 (3.5–5) mg and 23 (6.5–66.5) months, respectively. For each 1 mg dose reduction, morning and post-Synacthen cortisol rose by 48.8 nmol/L and 57.5 nmol/L (both P < 0.001), respectively, with reductions >2 mg producing larger cortisol increases than 1 mg reductions (both P < 0.05). Among completed wean attempts (n = 47), 81% (n = 38) were successful. Of these, 42% (n = 16) had a nadir morning cortisol <150 nmol/L, including six with values <28 nmol/L. No adrenal crises occurred. Conclusions: Physiological dose tapering in glucocorticoid-induced adrenal insufficiency enables, rather than follows, hypothalamic–pituitary–adrenal axis recovery, with structured, symptom-led tapering being safe and effective. Future guidelines should recognise that the HPA axis is suppressed by physiological doses. Significance statement: In this retrospective cohort study evaluating 65 adults with long-term glucocorticoid use for inflammatory disease undergoing prednisolone tapering, each 1 mg dose reduction from a maximum starting dose of 5 mg increased morning and post-Synacthen cortisol by 48.8 nmol/L and 57.5 nmol/L (both P < 0.001), respectively, with reductions >2 mg producing larger cortisol increases than 1 mg reductions (both P < 0.05). Furthermore, sixteen patients with a nadir morning cortisol <150 nmol/L, including six with values <28 nmol/L, were able to safely and successfully discontinue prednisolone. These findings have important implications for the management of glucocorticoid-induced adrenal insufficiency, with hypothalamic–pituitary–adrenal axis recovery driven by physiological dose reduction itself, and successful tapering enabling rather than following axis recovery. The routine use of short Synacthen tests in glucocorticoid-induced adrenal insufficiency is not supported by this study.